Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 106685-40-9] Adapalene

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0091
Brand:	MCE
CAS:	106685-40-9

Overview

MDL	MFCD03106112
Molecular Weight	412.52
Molecular Formula	C28H28O3
SMILES	COC1=C(C23CC4CC(C3)CC(C2)C4)C=C(C5=CC6=C(C=C(C(O)=O)C=C6)C=C5)C=C1

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

[1]Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118.
[2]Eur J Pharmacol. 2019 May 15;851:174-185.
[3]Fundam Clin Pharmacol. 2020 Jun;34(3):380-388.
[4]Katedra farmakologie a toxikologie. 2020 Jul.

Summary

Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC ₅₀ s of 2.3 nM, 9.3 nM, and 22 nM for RARβ , RARγ , RARα , respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity ^[1] ^[2] ^[3] .

IC50 & Target

AC50: 2.3 nM (RARβ), 9.3 nM (RARγ), and 22 nM (RARα) ^[1]

In Vitro

Adapalene (1-200 μM; 24 h) inhibits the viability of ES-2, HOV-7, MCF-7 , Hela, SW1990, HT1080, and MM-468 cells, with IC ₅₀ s of 10.36 μM, 10.81 μM, 12.00 μM, 19.08 μM, 19.52 μM, 21.70 μM, and 31.47 μM, respectively ^[2] .
Adapalene (10-40 μM; 24 h) induces ES-2 cells apoptosis and inhibits proliferation in vitro ^[2] .
Adapalene (3-30 μM; 6-24 h) significantly increases the G1-phase population in LoVo or DLD1 cells ^[3] .
Adapalene (1-200 μM) inhibits GOT1 activity, with an IC ₅₀ of 21.79 μM ^[2] .
Adapalene (10 ^-6 -10 ^-3 nM) inhibits the expression of plasma membrane-associated enzyme transglutaminase Type I, with an IC ₅₀ of 2.5 nM ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	Pancreatic cancer (SW1990, Aspc-1), breast cancer (mm-231, mm-468, MCF-7), liver cancer (Hep3B), cervical cancer (Hela), ovarian cancer (HOV-7, ES-2), normal cells (CHO, L929)
Concentration:	1-200 μM
Incubation Time:	24 hours
Result:	Inhibited the viability of cancer cells with higher GOT1 protein expression.

Apoptosis Analysis ^[2]

Cell Line:	ES-2 cells ^[2]
Concentration:	10, 20, 40 μM
Incubation Time:	24 hours
Result:	Showed a significant increase in apoptosis compared with the control group. Down regulated the expression of anti-apoptotic protein Bcl-2 and PARP.

Cell Cycle Analysis ^[3]

Cell Line:	LoVo or DLD1 cells
Concentration:	3, 10, 30 μM
Incubation Time:	6, 12, 24 hours
Result:	Caused cell cycle arrest in G1 phase in a dose- and time-dependent manner.

In Vivo

Adapalene (15-100 mg/kg; p.o. daily for 21 days) inhibits the growth of DLD1 cell-derived xenograft tumors in BALB/C nude mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/C nude mice (15 g, 4-5 weeks) were injected with DLD1 cells ^[3]
Dosage:	15, 20, 65, 100 mg/kg
Administration:	P.o. daily for 21 days
Result:	Significantly reduced tumor weight and volume.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03650361	Aleor Dermaceuticals Limited\|Catawba Research, LLC	Acne Vulgaris	September 17, 2018	Phase 3
NCT05582434	Wake Forest University Health Sciences\|Bausch Health Americas, Inc.	Acne	December 2022	Early Phase 1
NCT00599521	Galderma R&D	Acne Vulgaris	November 2007	Phase 3
NCT01182636	Teva Pharmaceuticals USA	Acne Vulgaris	July 2007	Phase 1
NCT03866447	Assiut University	Acne Vulgaris	October 1, 2019	Phase 4
NCT00719121	Stiefel, a GSK Company\|GlaxoSmithKline	Cutaneous Inflammation	November 2006	Phase 1
NCT03563365	Yardley Dermatology Associates\|Topix Pharmaceuticals, Inc	Acne Vulgaris	June 4, 2018	Phase 4
NCT01209949	Galderma R&D	Acne Vulgaris	October 2010	Phase 4
NCT01231334	Allergan	Acne Vulgaris	August 2010	Phase 4
NCT01213199	Galderma R&D	Acne Scars	March 2011	Phase 2
NCT04104685	Vyne Therapeutics Inc.	Acne Vulgaris	September 18, 2019	Phase 2
NCT00421993	Galderma R&D	Acne Vulgaris	October 2006	Phase 3
NCT00688064	Galderma R&D	Severe Acne Vulgaris	August 2008	Phase 3
NCT02338544	Galderma Laboratorium GmbH	Acne Vulgaris	January 2015
NCT02716090	Ache Laboratorios Farmaceuticos S.A.	Acne Vulgaris		Phase 3
NCT00919191	Bausch Health Americas, Inc.	Acne Vulgaris	April 2009	Phase 4
NCT01425320	Allergan	Acne Vulgaris	January 2013	Phase 1
NCT00647556	Galderma R&D	Photoaging	April 2008	Phase 3
NCT00907101	Galderma R&D	P Acnes Colonization	June 2009	Phase 4
NCT01046565	Galderma R&D	Skin Manifestations	January 2010	Phase 1
NCT00151541	Allergan	Acne Vulgaris	February 2005	Phase 3
NCT00671749	Galderma R&D	Acne Vulgaris	December 2007	Phase 4
NCT04329403	Aurobindo Pharma Ltd	Acne Vulgaris	July 2020	Phase 3
NCT02651220	Actavis Inc.	Acne	November 2015	Phase 3
NCT01742637	Taro Pharmaceuticals USA	Acne Vulgaris	October 2012	Phase 1
NCT00660985	Galderma R&D	Acne Vulgaris	May 2008	Phase 4
NCT02932267	Galderma R&D	Acne Vulgaris	February 2, 2017	Phase 3
NCT05536882	University of Oklahoma	Molluscum Contagiosum	February 2023	Phase 3
NCT03650881	NYU Langone Health	Acne	August 7, 2018	Not Applicable
NCT00441415	Galderma R&D	Acne Vulgaris	February 2007	Phase 3
NCT01095640	Actavis Mid-Atlantic LLC\|Actavis Inc.	Acne Vulgaris	March 2009	Not Applicable
NCT01406080	Galderma Brasil Ltda.	Photoaging\|Photodamage	January 2013	Phase 3
NCT00829049	Allergan	Acne Vulgaris	October 2007	Phase 4
NCT02173054	Mahidol University	Acne	July 2014	Phase 3
NCT01504204	Wake Forest University\|Galderma R&D\|Wake Forest University Health Sciences	Acne Vulgaris	December 2011	Phase 4
NCT00696449	Wake Forest University\|Wake Forest University Health Sciences	Acne Vulgaris	June 2006	Phase 4
NCT05096312	East Avenue Medical Center, Philippines	Acne Vulgaris	December 21, 2018	Phase 4
NCT02755545	Galderma R&D	Acne	May 1, 2016	Phase 4
NCT03393494	Padagis LLC	Acne Vulgaris	December 13, 2017	Phase 3
NCT00469755	Galderma R&D	Acne Vulgaris	February 2006	Phase 4
NCT02899000	Galderma R&D	Acne Vulgaris	July 29, 2016	Phase 4
NCT01618773	Galderma Laboratorium GmbH	Acne Vulgaris	June 2012
NCT00883233	Galderma R&D	Acne	April 2009	Phase 3
NCT02721173	All India Institute of Medical Sciences, Bhubaneswar	Acne Vulgaris	April 2016	Phase 4
NCT02411942	Taro Pharmaceuticals USA	Acne Vulgaris	August 2014	Phase 1
NCT01046396	Galderma R&D	Skin Manifestations	January 2010	Phase 1
NCT00714714	Bausch Health Americas, Inc.	Acne Vulgaris	January 2008	Phase 4
NCT01485367	Multispecialty Aesthetic Clinical Research Organization\|Galderma R&D	Senile Purpura	December 2011	Phase 2
NCT01501799	Actavis Mid-Atlantic LLC	Acne Vulgaris	July 2011	Not Applicable
NCT03615768	Lee´s Pharmaceutical Limited\|Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Acne Vulgaris	August 14, 2018	Phase 3
NCT02525549	Padagis LLC	Acne	December 2011	Phase 3
NCT02593383	Lee´s Pharmaceutical Limited	Acne	March 1, 2015	Phase 1\|Phase 2
NCT03626298	Rumah Sakit Pusat Angkatan Darat Gatot Soebroto	Acne Vulgaris	August 1, 2016	Phase 4
NCT04823845	Jonathan M Towarnicki\|University of Louisville	Plantar Wart	May 1, 2022	Early Phase 1
NCT00887484	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	February 2009	Phase 4
NCT02180425	University of California, Davis	Acne	November 2013
NCT00687908	Galderma R&D	Acne	November 2008	Phase 3
NCT05497323	Dr.dr.Irma Bernadette, SpKK (K)\|Indonesia University	Acne Vulgaris	August 1, 2022	Phase 1
NCT00964223	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	July 2009	Phase 4
NCT04797793	Taro Pharmaceuticals USA	Acne Vulgaris	May 18, 2020	Early Phase 1
NCT03585140	Centro Dermatológico Dr. Ladislao de la Pascua	Acne Vulgaris\|Diet Modification	January 1, 2016	Not Applicable
NCT00598832	Galderma R&D	Acne Vulgaris	November 2007	Phase 3
NCT00926367	Stiefel, a GSK Company\|GlaxoSmithKline	Acne Vulgaris	May 2009	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL ( 24.24 mM ; ultrasonic and warming and heat to 60°C)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4241 mL	12.1206 mL	24.2412 mL
5 mM	0.4848 mL	2.4241 mL	4.8482 mL
10 mM	0.2424 mL	1.2121 mL	2.4241 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 1 mg/mL (2.42 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1 mg/mL (2.42 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Shroot B, et, al. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103.
[2] Wang Q, et, al. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1. Bioorg Chem. 2019 Dec;93:103315.
[3] Shi XN, et, al. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. Mol Med Rep. 2015 Nov;12(5):6501-8.

Synonyms

2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.1^3,7]dec-1-ylphenyl)-

6-(4-Methoxy-3-tricyclo[3.3.1.1^3,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid

CD 271

Adapalene

Differin

6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid

Differin Gel

6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid

CD 271 (pharmaceutical)

Aclene Gel

Aclene

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart